InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,463.54
(
0.08%
)
US TECH 100
18,480.00
(
-0.21%
)
Dow Jones
40,539.93
(
-0.12%
)
Brent Oil
78.70
(
-0.57%
)
Bitcoin
66,632.46
(
-0.29%
)
Post# of 252727
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bladerunner1717

Send PM Follow Ignore
Followers 38
Posts 5652
Boards Moderated 0
Alias Born 11/09/2003

bladerunner1717

Re: Mufaso post# 217964

Saturday, 03/17/2018 11:17:24 PM

Saturday, March 17, 2018 11:17:24 PM

Post# of 252727

The MYLAN deal is not to commercialize RT002 but rather an agreement to develop a biosimilar. The Mylan deal is for a different (new) compound that mimics Allergan’s Botox and its associated shorter duration.



How is the "biosimilar" different from the drug that RVNC is developing?

If the "biosimilar" is for a "new compound," then how is it a "biosimilar?"


Bladerunner
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up